GENEVA, Aug. 7 -- ERASCA, INC. filed a patent application (US2026/012663) for “HAS AND CTLA-4 INHIBITORS COMBINATION THERAPY FOR THE TREATMENT OF CANCER”. With publication no. WO/2026/165003, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 31/504

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....